MedTrace Logo

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

NCT05511025 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2023-12-26

No results posted yet for this study

Summary

A study in healthy male and female participants of non-childbearing potential who are overweight or obese.

Conditions

  • Healthy Participants

Interventions

DRUG

AZD6234

Participants will receive a single dose of AZD6234 as a solution via SC or IV injection

DRUG

Placebo

Participants will receive matching volumes of the placebo as a solution via SC or IV injection

COMBINATION_PRODUCT

Acetaminophen

Participants will receive a single dose of acetaminophen as part of a meal

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-20
Primary Completion
2023-12-19
Completion
2023-12-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05511025 on ClinicalTrials.gov